Page contents Key factsDecisionRelated medicine informationKey facts Invented name Piqray Active Substance Alpelisib Therapeutic area Congenital, familial and genetic disorders Decision number P/0090/2024 PIP number EMEA-002016-PIP05-23 Pharmaceutical form(s) Film-coated tabletAge-appropriate formulation Condition(s) / indication(s) Treatment of lymphatic malformations associated with a PIK3CA mutation Route(s) of administration Oral use Contact for public enquiries Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111 Decision type P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) Decision date 12/04/2024DecisionP/0090/2024: EMA decision of 12 April 2024 on the agreement of a paediatric investigation plan for alpelisib (Piqray), (EMEA-002016-PIP05-23)AdoptedReference Number: EMA/137677/2024 English (EN) (214.8 KB - PDF)First published: 06/06/2025ViewRelated medicine informationPiqrayShare this page